We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A five‐year follow‐up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial.
- Authors
Offner, Fritz; Robak, Tadeusz; Janssens, Ann; Govind Babu, K.; Kloczko, Janusz; Grosicki, Sebastian; Mayer, Jiri; Panagiotidis, Panagiotis; Schuh, Anna; Pettitt, Andrew; Montillo, Marco; Werner, Olena; Vincent, Ghislaine; Khanna, Sadhvi; Hillmen, Peter
- Abstract
The Complement 1 trial investigated the efficacy and safety of ofatumumab + chlorambucil with chlorambucil monotherapy in patients with previously untreated chronic lymphocytic leukaemia (CLL). On long‐term follow‐up in the chemoimmunotherapy arm vs. the chemotherapy arm there was an estimated 12% (not significant) and 39% risk reduction in overall survival and progression‐free survival, respectively. A high rate (61%) of treatment with next‐line therapies in both the treatment arms may dilute any potential OS difference and confound the interpretation of the OS results. Addition of ofatumumab to chlorambucil demonstrated clinical benefit and tolerability as a frontline treatment option in patients unfit for fludarabine‐containing therapy, with no new safety concerns.
- Subjects
CHRONIC leukemia; LYMPHOCYTIC leukemia; PROGRESSION-free survival; CHRONIC lymphocytic leukemia; VOLTAGE
- Publication
British Journal of Haematology, 2020, Vol 190, Issue 5, p736
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.16625